Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have earned an average recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $78.5556.

A number of brokerages have recently commented on HALO. Benchmark boosted their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday. Citizens Jmp lifted their price target on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research note on Tuesday, November 4th. The Goldman Sachs Group restated a “sell” rating and set a $56.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Saturday. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th.

Halozyme Therapeutics Stock Down 1.5%

HALO stock opened at $70.98 on Tuesday. The company has a debt-to-equity ratio of 43.89, a current ratio of 4.66 and a quick ratio of 1.37. The stock has a market capitalization of $8.38 billion, a P/E ratio of 28.51, a P/E/G ratio of 0.29 and a beta of 0.97. Halozyme Therapeutics has a fifty-two week low of $47.50 and a fifty-two week high of $82.22. The business has a 50-day moving average of $72.14 and a 200-day moving average of $70.43.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The firm had revenue of $451.77 million during the quarter, compared to analyst estimates of $446.13 million. During the same period in the prior year, the business posted $1.26 EPS. The firm’s quarterly revenue was up 51.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Halozyme Therapeutics will post 4.73 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the transaction, the director directly owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. This trade represents a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $76.12, for a total transaction of $1,522,400.00. Following the transaction, the chief executive officer owned 708,719 shares in the company, valued at approximately $53,947,690.28. The trade was a 2.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 49,398 shares of company stock worth $3,650,592 in the last ninety days. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of HALO. CWM LLC raised its stake in Halozyme Therapeutics by 2,136.0% in the 3rd quarter. CWM LLC now owns 23,881 shares of the biopharmaceutical company’s stock valued at $1,751,000 after acquiring an additional 22,813 shares during the period. Arbor Investment Advisors LLC bought a new position in Halozyme Therapeutics during the third quarter worth $1,316,000. Monument Capital Management acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at $2,015,000. Pacer Advisors Inc. raised its position in shares of Halozyme Therapeutics by 2,054.7% in the third quarter. Pacer Advisors Inc. now owns 478,874 shares of the biopharmaceutical company’s stock valued at $35,121,000 after purchasing an additional 456,649 shares during the period. Finally, Cardinal Capital Management bought a new position in shares of Halozyme Therapeutics in the third quarter valued at about $1,303,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.